OQS
VTGN icon

Occudo Quantitative Strategies’s VistaGen Therapeutics VTGN Stock Holding History

Occudo Quantitative Strategies’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,038
Closed -$39.1K – 944
2025
Q4 		$39.1K Buy
59,038
+16,334
+38% +$59K ﹤0.01% 667
2025
Q3 		$152K Buy
+42,704
New +$128K 0.02% 601
2022
Q3 		– Sell
-2,965
Closed -$78K – 1428
2022
Q2 		$78K Hold
2,965
– – 0.01% 1036
2022
Q1 		$110K Hold
2,965
– – 0.01% 1012
2021
Q4 		$173K Sell
2,965
-169
-5% -$11K 0.02% 912
2021
Q3 		$258K Buy
+3,134
New +$272K 0.03% 785

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Occudo Quantitative Strategies's VTGN Position: Q1 2026 in Review

Occudo Quantitative Strategies sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 59,038 shares — an estimated $39.1K sold.

Occudo Quantitative Strategies first reported a position in VTGN in Q3 2021 and held it in 6 quarters. The position peaked at $258K in Q3 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Occudo Quantitative Strategies reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 59,038 VistaGen Therapeutics shares in Q1 2026, an estimated $39.1K.
  • Occudo Quantitative Strategies first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 6 quarters.
  • Occudo Quantitative Strategies's VistaGen Therapeutics position peaked at $258K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2026, filed 15 May 2026.